Vector ablation of peripheral nerves

A neurotropic vector encoding a cleavable protease induces apoptosis in peripheral nerves, addressing residual pain and neuroma formation post-amputation by administering AAV9 with tissue-specific promoters, achieving effective pain relief and motor neuron preservation.

WO2026128852A1 Publication Date: 2026-06-18JOHNS HOPKINS UNIVERSITY
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
JOHNS HOPKINS UNIVERSITY
Filing Date
2025-12-12
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

Current treatments for nerve pain and neuroma formation after amputation, such as traction neurectomy, TMR, RPNI, and VDMT, fail to adequately address residual pain in a significant proportion of patients, leading to lifelong opioid usage and debilitating symptoms.

⚗Method used

Administration of a pharmaceutical composition containing a neurotropic vector encoding a cleavable protease and a protease-specific cleaving enzyme, which induces apoptosis of neurons through expression of activated caspase-3, using AAV serotype 9 with tissue-specific promoters to target peripheral nerves.

🎯Benefits of technology

Effectively ablates nerves, reducing pain and neuroma-related symptoms, minimizing opioid usage, and preserving motor neuron function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

In one aspect, nerve ablation methods in the treatment of neurological diseases and disorders utilize AAV capsids which are taken up by peripheral nerves after local injection in the periphery. Compositions include vectors with genetic material encoding enzymes that induce apoptosis under a neuron-specific promoter.
Need to check novelty before this filing date? Find Prior Art